Appili Therapeutics was founded to acquire, develop, and commercialize novel therapeutics addressing biodefense and infectious disease priorities. Today, we are expanding that foundation into a broader National Security Healthcare company focused on technologies that protect military personnel, strengthen national resilience, and address high-priority healthcare needs. This evolution positions Appili at the intersection of healthcare innovation, government priorities, and growing demand for medical preparedness and protection.
Our defense and health-security portfolio is designed to identify and advance solutions addressing high-priority national security and healthcare needs. We seek opportunities across biodefense, physiological readiness, diagnostics, biosurveillance, infectious disease and protection against chemical, biological, radiological, and nuclear threats.
A key focus is dual-use innovation—including therapeutics, diagnostics, medical devices, and manufacturing capabilities—with potential applications across defense, government, and commercial healthcare markets. This approach allows Appili to pursue opportunities with multiple potential development, funding, procurement, and commercialization pathways.
Appili brings together regulatory and drug development with partnership experience to advance medical technologies for biodefence and national security healthcare
Experience navigating emergency use authorization frameworks and pre-EUA development pathways to support expedited regulatory strategies.
Drug development and regulatory expertise involving neglected tropical diseases and rare pediatric indications with potential PRV value.
Experience working with government funding programs, procurement agencies and strategic research partners.
Understanding military and homeland security requirements, medical countermeasure needs and stockpiling considerations.
Near to market/revenue or
commercial opportunities
Transformational programs to
tackle the most serious threats
An important aspect of this approach to portfolio-building is discipline – Appili’s team has reviewed and passed on more than 150 drug development projects that did not meet our rigorous scientific, clinical, patient-care, and strategic corporate criteria. The inherent flexibility in our approach also allows us to pursue opportunities that provide access to non-dilutive funding from government incentive programs or industry partnerships.
A shared technology opportunity across defense preparedness and civilian healthcare markets.
Announced Funding
from the U.S.
Department of War
2025 Medicare
benefit payments
2025 total hospital
expenditures
Develop medical countermeasures to protect deployed personnel and pursue government procurement for defined readiness needs
Develop medicines for patients and work with commercial or global health partners to make them available
Fund Appili for validation, advance technology without diluting shareholders
Successful technology earn Appili procurement revenue or stockpile contracts, even before commercial launch
Appili can then commercialize the same technology in the private sector / civilian applications